Authors
Yirong Huang, Ting Pan, Xin Shi, Guoqiang Zhang, Fang Cheng, Songmei Geng, Heng Gu, Shanshan Li, Qingchun Diao, Xiaohua Wang, Yonghong Lu, Chao Ji, Yuzhen Li, Yuling Shi, Jun Gu, Lingling Chen
Published in
Dermatology and therapy. Sep 06, 2026. Epub Sep 06, 2026.
Abstract
Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha, has been approved for the treatment of severe plaque psoriasis in children aged 4 years and older. Data on its use in the clinical management of pediatric psoriasis in China remains limited. This study is the first prospective analysis of the adalimumab biosimilar (GELELI®, the first biosimilar of adalimumab approved in China, and QLETLI® in the UK) safety and effectiveness for severe pediatric plaque psoriasis in China.
Weight-based dosage was administered to 80 patients (ages 4-18 years) from multiple centers. Primary endpoints included the proportions of patients achieving PASI75 and PGA 0/1 at week 16.
The mean psoriasis area and severity index (PASI) score decreased from 15.31 ± 8.375 at baseline to 6.29 ± 4.208 at week 4. PASI 50/90/100 response rates were 91.1%, 49.4%, and 21.5% at week 12. At week 16, 81.0% and 68.4% of patients attained PASI75 and PGA 0/1, respectively. The incidence of adverse events was 82.5%. Adverse drug reactions accounted for 62.5%. No serious adverse events were reported.
The biosimilar demonstrates efficacy and safety in the treatment of Chinese children with severe plaque psoriasis, consistent with clinical trial data for the originator drug.
Clinicaltrials.gov: NCT05803187.
PMID:
42701929
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0